Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Clinical trial NCT04664244 · UNKNOWN

Trial details

NCT number: NCT04664244
Sponsor: Lei Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Cervical Carcinoma Radiotherapy Epidermal Growth Factor Receptor Nimotuzumab Objective Response Rate Progression-free Survival Overall Survival

Start date: 2020-12-19
Primary completion: 2023-12-31
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.